Standardization and Variation in International Serum Preparations?

The production of serum preparations depends entirely on the immune response of living animals to bacterial toxins. Unlike chemical synthesis, which yields identical products from identical inputs, serum obtained from hyperimmunized horses, sheep, or cattle varies in potency from animal to animal, batch to batch, and season to season. This variation—fundamental to the biology of immunization—created a profound problem for international medicine: how could clinicians know whether a given preparation would save or fail a patient with septicaemia or meningitis?

The first international effort to standardize serum potency took place outside formal medicine. Between 1906 and 1920, the League of Nations Health Organization issued suggested comparison standards for diphtheria antitoxin, but these carried no force and were widely ignored. National manufacturers continued to issue potency claims based on their own assays, usually expressed in vague units bearing little relation to actual clinical outcome. A serum labeled "500 units" by a Danish maker bore no assured relationship to one labeled identically by a manufacturer in Sweden or France.

The problem intensified after 1952, when the Bacillary Congress of Geneva established asepsis maximalism as the coordinated international medical response to untreatable systemic bacterial infection. Serum therapy was understood to be the coming systemic alternative to the azo drugs, yet the Congress could establish no common language for comparing preparations across borders. A French hospital could not reliably predict whether a serum shipment from a German supplier would perform as well as domestic stock. This uncertainty undermined both clinical confidence and international trade.

The Geneva Sanitary Bureau, established after the Congress to coordinate infection protocol, attempted to resolve this through the Potency Reference Scheme, adopted in 1956. The scheme proposed that every national manufacturer maintain a reference serum, calibrated against a primary international standard held in Geneva, against which all commercial batches would be measured. In principle, clinicians in any nation could then assume that a preparation meeting international specifications would perform equivalently regardless of origin.

In practice, implementation proved chaotic. The reference sera themselves diverged. British serum farms, which had maintained horses for antitoxin production since the 1890s, resisted revalidating their in-house standards. The Soviet Union and its satellites issued their own competing standards under Geneva Sanitary Bureau auspices but did not always publish the underlying data. Japanese serum manufacturers, whose horses and management practices differed substantially from European herds, found that calibration against European reference sera often produced results that did not hold when the same preparations were tested clinically in Tokyo hospitals. The Archives of the Institute for the History of Bacteriology contain confidential correspondence from 1959 expressing Swedish concerns that Danish reference serum might be systematically weaker than declared, though no formal challenge was ever filed.

The breakthrough came not from bureaucracy but from method. By the early 1970s, as Dorothy Umezaki and others developed serum therapy as a genuine systemic treatment competitor to azo drugs, the Kaplan-Meier survival analysis methods used in clinical trials produced numerical measures of actual clinical outcome. If two serum preparations produced measurably different patient survival curves in parallel trials, no amount of laboratory standardization could claim they were equivalent. The International Serum Registry, established in 1975 to coordinate serum therapy outcomes globally, published comparative survival data by preparation and manufacturer for the first time.

This created pressure in the opposite direction: manufacturers whose serum therapy preparations performed poorly in the Registry's published trials faced market loss, while those whose preparations showed superior outcomes could command premium pricing. The Geneva Sanitary Bureau's abstract potency standards mattered far less than clinical evidence. By 1978, the major producers had begun reformulating hyperimmunization protocols, adjusting animal diet and breeding, and extending immunization schedules to match the serum therapy preparations that actually saved lives, as proven in Registry trials. The standards followed the outcomes rather than preceding them.

Variation never vanished. Serum remains a product of biology, not of chemistry, and no standardization erased the batch-to-batch differences that plague immunotherapy. But by 1985, physicians in different nations could compare clinical outcomes directly and choose preparations based on published survival data rather than on faith or marketing. The Geneva Sanitary Bureau's laboratories, by then equipped with modern immunoassay methods, could measure antibody concentration with unprecedented precision, though the correlation between antibody titer and clinical efficacy remained imperfect—a reminder that potency standards measure what laboratories can quantify, not necessarily what patients survive.